Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The recent application of high-throughput sequencing to NHL not only advances the understanding of disease pathogenesis and classification, but allows the discovery of new drug targets, such as BRAF gene inhibition in hairy cell leukemia.
|
27910030 |
2017 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Many such genetic events have already demonstrated clinical utility, such as BRAF V600E that confers sensitivity to vemurafenib in patients with hairy cell leukemia.
|
29702524 |
2018 |
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
To the best of our knowledge, this is the first case of a co-occurring BRAF positive melanoma and HCL to be reported in a chemotherapy-naïve patient.
|
30680261 |
2018 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Besides confirming the constant presence of BRAF-V600E in all patients with hairy cell leukemia, we observed ubiquitous phospho-ERK expression in this malignancy.
|
23349307 |
2013 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of 3 or 4 based on the CD11C, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral medullary infiltration and the presence of BRAF V600E somatic mutation.
|
29110361 |
2017 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The precise cellular origin of HCL remains elusive but BRAF mutations were detected in hematopoietic stem cells of patients with HCL.
|
26154707 |
2015 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Diagnostically, the BRAF(V600E) mutation is a powerful molecular marker for papillary thyroid carcinoma and, quite possibly, hairy cell leukemia as well.
|
22369373 |
2012 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Hairy cell leukemia (HCL) is a rare, low-grade mature B-cell neoplasm with a characteristic clinical, morphological, immunophenotypic, and more recently described molecular (BRAF p.V600E mutation) profile.
|
30197362 |
2018 |
Hairy Cell Leukemia
|
0.600 |
SomaticCausalMutation
|
disease |
ORPHANET |
In immunohistologic and Western blot studies, HCL cells expressed phosphorylated MEK and ERK (the downstream targets of the BRAF kinase), indicating a constitutive activation of the RAF-MEK-ERK mitogen-activated protein kinase pathway in HCL.
|
21663470 |
2011 |
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Several genetic alterations are intuitively "druggable" with existing agents, for example, kinase-activating lesions in high-risk B-cell ALL, NOTCH1 in both leukemia and lymphoma, and BRAF in hairy cell leukemia.
|
24041576 |
2013 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The intestinal lymphoma bears the BRAF V600E mutant, which is the molecular hallmark of HCL, being implicated in its pathogenesis.
|
31354304 |
2019 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Importantly, SkE resensitized the PLX-4032-resistant 451Lu melanoma cell line (451Lu-R) and was more efficient than U0126, a MEK inhibitor, and PLX-4032 (PLX) at inducing the apoptosis of two hairy cell leukemia (HCL) patient samples carrying the B-Raf-V600E mutation.
|
23518796 |
2012 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Unearthing of the BRAF mutation in self-renewing hematopoietic stem cells reveals an unexpected origin for hairy cell leukemia-a mature B cell malignancy-and a potential new therapeutic target (Chung et al., this issue).
|
24871129 |
2014 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies.
|
21910720 |
2011 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this issue of Blood, Pettirossi et al, including Drs Tiacci and Falini, who led the effort in 2011 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory studies showing that inhibitors of BRAF-V600E and/or mitogen-activated protein kinase kinase (MEK) reach their targets and cause HCL cell death
|
25700421 |
2015 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study we investigated the application of a BRAF V600E mutation-specific antibody (clone VE1) to differentiate HCL from HCL mimics, such as HCL variant and splenic marginal zone lymphoma.
|
22531170 |
2012 |
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results suggest that HCLv and IGHV4-34(+) HCLs have a different pathogenesis than HCLc and that a significant minority of other HCLc are also wild-type for BRAF V600.
|
22210875 |
2012 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The discovery of the BRAF V600E mutation in most cases of classical hairy cell leukemia opens up unique opportunities for tumor specific treatment of HCL targeting the MEK/ERK signaling pathway.
|
26614903 |
2015 |
Hairy Cell Leukemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.
|
26352686 |
2015 |
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
An overview of the major forms of treatment of HCL (cytostatic drugs, specific BRAF inhibitors, B cell-specific antibodies) is given.
|
31282776 |
2019 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In order to investigate the suitability of MinION sequencing on formalin-fixed paraffin-embedded samples, the presence and frequency of BRAF c.1799T > A mutation was investigated in two archival tissue specimens of Hairy cell leukemia and Hairy cell leukemia Variant.
|
29238890 |
2018 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutation of BRAF V600E was pronounced in HCL, but "hairiness" was not linked to the mutation.
|
31538423 |
2019 |
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Patients' leukemic cells exposed ex vivo to BRAF inhibitors are spoiled of their HCL identity and then undergo apoptosis.
|
28297625 |
2017 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using this BRAF V600E mutation specific antibody, this immunohistochemical study has 100% sensitivity and 100% specificity for the diagnosis of HCL in our cohort.
|
25120816 |
2014 |
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the presence of pERK as detected by immunohistochemical staining is a useful surrogate marker for BRAF V600E in the diagnosis of HCL.
|
23211289 |
2013 |